• Up to $5 million of standby equity capital
• Utilisation at Noxopharm's discretion
• No requirements to utilise the ATM, can terminate at any time

Noxopharm Limited (ASX:NOX), an innovative biotech company, has announced the signing of an At-the-Market Subscription Agreement (ATM) with Acuity Capital. The ATM provides Noxopharm with up to $5 million of standby equity capital over the next five years to 31 July 2031. Noxopharm has full discretion as to whether or not to utilise the ATM, the maximum number of shares to be issued, the minimum issue price of shares, and the timing of each subscription (if any). There are no requirements on Noxopharm to utilise the ATM, and Noxopharm may terminate the ATM at any time without cost or penalty. Additionally, Acuity Capital and the ATM do not place any restrictions at any time on Noxopharm raising capital through other methods. If Noxopharm decides to utilise the ATM, it can set an issue price floor at its sole discretion, with the final issue price being calculated as the greater of the nominated floor price and up to a 10% discount to a Volume Weighted Average Price (VWAP) over a period of Noxopharm's choosing, again at its sole discretion. As security for the ATM, Noxopharm has agreed to place 15,000,000 fully paid ordinary NOX ASX shares from its LR7.1 capacity at nil cash consideration to Acuity Capital. Upon early termination or maturity of the ATM, Noxopharm may buy back and cancel the shares placed as security for no cash consideration, subject to shareholder approval.